ICU Medical financials
$163.44−0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B | $1.27B | $1.40B | $1.29B | $379.4M |
| Gross profit | $822.0M | $824.8M | $739.9M | $697.8M | $491.5M | $461.5M | $471.9M | $570.0M | $426.1M | $201.4M |
| Gross margin | 36.8% | 34.6% | 32.8% | 30.6% | 37.3% | 36.3% | 37.3% | 40.7% | 33.0% | 53.1% |
| Operating income | $42.8M | $43.0M | $22.8M | -$42.9M | $141.3M | $98.2M | $107.4M | $29.8M | -$13.3M | $82.9M |
| Net income | $732.0K | -$117.7M | -$29.7M | -$74.3M | $103.1M | $86.9M | $101.0M | $28.8M | $68.6M | $63.1M |
| Net margin | 0.0% | −4.9% | −1.3% | −3.3% | 7.8% | 6.8% | 8.0% | 2.1% | 5.3% | 16.6% |
| Diluted EPS | $0.03 | $-4.83 | $-1.23 | $-3.11 | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 |
| EBITDA | $310.1M | $322.3M | $292.9M | $258.1M | $241.2M | $229.4M | $231.5M | $271.9M | $139.2M | $118.1M |
| Operating cash flow | $179.8M | $204.0M | $166.2M | -$30.0M | $267.5M | $222.8M | $101.9M | $160.2M | $154.4M | $89.9M |
| Free cash flow | $91.8M | $124.7M | $82.3M | -$120.3M | $199.0M | $130.7M | $4.6M | $67.5M | $79.9M | $66.6M |
| Diluted shares | 24.9M | 24.4M | 24.1M | 23.9M | 21.8M | 21.6M | 21.5M | 21.6M | 20.9M | 17.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $308.0M | $308.6M | $254.2M | $208.8M | $552.8M | $396.1M |
| Short-term investments | $0.00 | $0.00 | $501.0K | $4.2M | $14.4M | $14.7M |
| Total debt | $1.28B | $1.58B | $1.63B | $1.65B | $0.00 | $0.00 |
| Total assets | $4.05B | $4.20B | $4.38B | $4.52B | $1.88B | $1.76B |
| Total liabilities | $1.93B | $2.24B | $2.26B | $2.43B | $264.7M | $261.4M |
| Shareholders' equity | $2.12B | $1.97B | $2.12B | $2.09B | $1.62B | $1.50B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology